Real-world evidence on JAK inhibitors in rheumatology practice: comparative safety, efficacy, and outcomes between JAK inhibitors - PubMed
4 hours ago
- #Real-world evidence
- #JAK inhibitors
- #Rheumatology
- Study compares real-world drug survival, safety, and prescribing patterns of three JAK inhibitors (tofacitinib, baricitinib, upadacitinib) in rheumatic diseases.
- Tofacitinib had the highest 6-month survival rate (81.9%) and was most often first-line; upadacitinib had the lowest (69.6%) and was typically used after advanced therapy failure.
- Secondary non-response was the primary reason for discontinuation, with adverse events accounting for less than 10%.
- JAK inhibitors showed favorable retention and safety across various inflammatory rheumatic diseases, regardless of prior biologic exposure.
- Upadacitinib demonstrated high continuation rates even in refractory cases, highlighting its role as a viable late-line treatment option.